Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DGX 
Quest Diagnostics Incorporated (DGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: DGX (1-star) is a SELL. SELL since 4 days. Profits (1.92%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -17.71% | Avg. Invested days 34 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 18.64B USD | Price to earnings Ratio 21.84 | 1Y Target Price 177.09 |
Price to earnings Ratio 21.84 | 1Y Target Price 177.09 | ||
Volume (30-day avg) 1186708 | Beta 0.92 | 52 Weeks Range 123.53 - 178.87 | Updated Date 04/2/2025 |
52 Weeks Range 123.53 - 178.87 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 1.89% | Basic EPS (TTM) 7.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.82% | Operating Margin (TTM) 14.04% |
Management Effectiveness
Return on Assets (TTM) 5.84% | Return on Equity (TTM) 13.84% |
Valuation
Trailing PE 21.84 | Forward PE 17.42 | Enterprise Value 25324367520 | Price to Sales(TTM) 1.89 |
Enterprise Value 25324367520 | Price to Sales(TTM) 1.89 | ||
Enterprise Value to Revenue 2.57 | Enterprise Value to EBITDA 13.37 | Shares Outstanding 110978000 | Shares Floating 110376568 |
Shares Outstanding 110978000 | Shares Floating 110376568 | ||
Percent Insiders 0.44 | Percent Institutions 93.42 |
Analyst Ratings
Rating 3.94 | Target Price 170.4 | Buy 1 | Strong Buy 8 |
Buy 1 | Strong Buy 8 | ||
Hold 9 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quest Diagnostics Incorporated
Company Overview
History and Background
Quest Diagnostics was founded in 1967 as Metropolitan Pathology Laboratory, Inc. It became a spin-off from Corning Incorporated in 1996 and rebranded as Quest Diagnostics. The company has grown significantly through acquisitions and organic growth, becoming a leading provider of diagnostic information services.
Core Business Areas
- Diagnostic Information Services: Provides a broad range of clinical laboratory tests, anatomic pathology services, and other diagnostic information services to patients, clinicians, hospitals, and employers.
Leadership and Structure
The current CEO of Quest Diagnostics is James E. Davis. The company has a typical corporate structure with executive leadership overseeing various functional areas like operations, finance, and sales.
Top Products and Market Share
Key Offerings
- Routine Clinical Testing: Includes blood tests, urine tests, and other common diagnostic tests. It is the largest segment, accounting for a significant portion of revenue. Competitors include Labcorp, Mayo Clinic Laboratories, and regional labs. Market share is difficult to accurately quantify without proprietary data but is estimated to be competitive with Labcorp.
- Advanced Diagnostics: Includes molecular diagnostics, genetic testing, and other specialized tests. This segment is growing rapidly due to advancements in personalized medicine. Competitors include Myriad Genetics, Invitae, and Genomic Health. Market share varies depending on the specific test, with competition across different players.
- Employer Population Health Services: Includes drug testing, wellness programs, and other services aimed at managing employee health. Competitors include Labcorp and other occupational health providers. Market share is competitive and depends on specific service offerings.
Market Dynamics
Industry Overview
The diagnostic testing industry is characterized by increasing demand for advanced diagnostics, consolidation among providers, and regulatory pressures. Technological advancements are driving growth in personalized medicine and point-of-care testing.
Positioning
Quest Diagnostics is one of the two largest players in the U.S. diagnostic testing market, known for its extensive network of labs and patient service centers. Its competitive advantages include its scale, brand recognition, and comprehensive test menu.
Total Addressable Market (TAM)
The global in-vitro diagnostics market is estimated to be worth hundreds of billions of dollars annually. Quest Diagnostics is well-positioned to capture a significant portion of this market through its broad service offerings and extensive network.
Upturn SWOT Analysis
Strengths
- Extensive network of labs and patient service centers
- Broad test menu
- Strong brand recognition
- Established relationships with healthcare providers and payers
- Scale and efficiency
Weaknesses
- Dependence on reimbursement rates
- Exposure to regulatory changes
- Competition from other large and regional labs
- Potential for technological disruption
- High capital expenditure
Opportunities
- Growth in advanced diagnostics and personalized medicine
- Expansion into new markets
- Strategic acquisitions
- Development of new technologies and services
- Partnerships with healthcare providers and technology companies
Threats
- Reimbursement cuts
- Increased competition
- Technological obsolescence
- Economic downturn
- Regulatory changes
Competitors and Market Share
Key Competitors
- LH
- DGX
- CVS
Competitive Landscape
Quest Diagnostics faces intense competition from other large and regional labs. Its advantages include its scale, brand recognition, and comprehensive test menu. Its disadvantages include its dependence on reimbursement rates and exposure to regulatory changes.
Major Acquisitions
PathAI Diagnostics
- Year: 2024
- Acquisition Price (USD millions): 100
- Strategic Rationale: Expand digital pathology capabilities and accelerate growth in oncology diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Quest Diagnostics has experienced consistent growth over the past years, driven by acquisitions, organic growth, and increasing demand for diagnostic testing.
Future Projections: Analyst estimates project continued growth for Quest Diagnostics, driven by the growth in the diagnostic testing market and the company's strategic initiatives. Projections depend on market conditions and company-specific factors.
Recent Initiatives: Recent strategic initiatives include acquisitions of smaller diagnostic labs, partnerships with healthcare providers, and investments in new technologies.
Summary
Quest Diagnostics is a strong company and a major player in the diagnostic testing market with a wide testing portfolio and an extensive network. The company is facing increasing competition and is dependent on reimbursement rates, so it should look out for technological changes. DGX is well-positioned for continued growth, focusing on strategic acquisitions and partnerships to capitalize on opportunities. However, reimbursement pressures and the need to innovate remain crucial considerations.
Similar Companies
CI
Cigna Corp
CI
Cigna Corp
CVS
CVS Health Corp
CVS
CVS Health Corp
HUM
Humana Inc
HUM
Humana Inc
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
UNH
UnitedHealth Group Incorporated
UNH
UnitedHealth Group Incorporated
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market conditions and company performance are subject to change. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quest Diagnostics Incorporated
Exchange NYSE | Headquaters Secaucus, NJ, United States | ||
IPO Launch date 1996-12-17 | Chairman, CEO & President Mr. James E. Davis | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 45000 | Website https://www.questdiagnostics.com |
Full time employees 45000 | Website https://www.questdiagnostics.com | ||
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.